Strategic Focus Private clinical-stage biotech focusing on localized targeted therapies using proprietary JEL Technology across Dermatology, Ophthalmology, Urology, and Oncology. Potential sales angle: partner or license opportunities with larger pharma firms seeking differentiated delivery platforms and niche unmet medical needs.

Pipeline Footprint Historical emphasis on AIV001 and AIV007 programs with emphasis on vision loss from wet AMD and dermal applications. Suggest exploring collaboration or co-development deals to expand indications and accelerate timelines leveraging JEL technology.

Early Stage Momentum Company has launched early phase studies (Phase 1/2a for AIV001 in dermal scarring) and has added new board leadership, signaling growth and governance readiness. Sales approach can target early commercial planning and capacity discussions with larger partners and contract manufacturers.

Financial Signals Reported revenue in the modest range with minimal disclosed funding, indicating capital-efficient operations but potential needs for strategic financing to scale. Opportunities exist for milestone-driven partnerships, co-funding, or licensing that align with development milestones.

Market Positioning Niche focus on reducing systemic exposure and addressing unmet medical needs through JEL technology positions AiViva as a specialized partner for specialty therapeutic areas. Target dermatology, ophthalmology, urology, and oncology product developers seeking novel delivery tech or early-stage assets with differentiated profiles.